High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo

Tissue Engineering - Part A

Volumn 17, Issue 9-10, 2011, Pages 1389-1399

  Zara, Janette N ^a,b   Siu, Ronald K ^a,b   Zhang, Xinli ^b   Shen, Jia ^a,b   Ngo, Richard ^b   Lee, Min ^b   Li, Weiming ^b,c   Chiang, Michael ^b   Chung, Jonguk ^b   Kwak, Jinny ^b   Wu, Benjamin M ^a   Ting, Kang ^a,b   Soo, Chia ^d  

^a Department of Civil and Environmental Engineering   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONCENTRATION (PROCESS); DEFECTS; PROTEINS;

ADIPOSE TISSUE; ADVERSE EFFECT; BONE FORMATION; BONE MORPHOGENETIC PROTEIN-2; BONE MORPHOGENETIC PROTEINS; CLINICAL EFFECTS; CLINICAL USE; CONCENTRATION RANGES; DEFECT MODEL; DOSE-DEPENDENT; HIGH DOSE; IN-VIVO; SIDE EFFECT; SOFT TISSUE; TOTAL DOSE;

BONE;

RATTUS;

GELATINASE A; MMP2 PROTEIN, HUMAN;

ADIPOSE TISSUE; ANIMAL; ARTICLE; BONE CYST; BONE DEVELOPMENT; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; FEMUR; FEMUR FRACTURE; HUMAN; LEWIS RAT; MALE; METABOLISM; PATHOLOGY; RAT;

ADIPOSE TISSUE; ANIMALS; BONE CYSTS; DISEASE MODELS, ANIMAL; FEMORAL FRACTURES; FEMUR; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; OSTEOGENESIS; RATS; RATS, INBRED LEW;

EID: 79955022472     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2010.0555     Document Type: Article

References (54)

1. Carlisle, E., and Fischgrund, J.S. Bone morphogenetic proteins for spinal fusion. Spine J 5, 240S, 2005.
2. McKay, B., and Sandhu, H.S. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 27, S66, 2002.
3. Walker, D.H., and Wright, N.M. Bone morphogenetic proteins and spinal fusion. Neurosurg Focus 13, 1, 2002.
4. Wong, D.A., Kumar, A., Jatana, S., Ghiselli, G., and Wong, K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 8, 1011, 2008.
5. Kaneko, H., Arakawa, T., Mano, H., Kaneda, T., Ogasawara, A., Nakagawa, M., et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27, 479, 2000.
6. Smucker, J.D., Rhee, J.M., Singh, K., Yoon, S.T., and Heller, J.G. Increased swelling complications associated with offlabel usage of rhBMP-2 in the anterior cervical spine. Spine 31, 2813, 2006.
7. Vaidya, R., Carp, J., Sethi, A., Bartol, S., Craig, J., and Les, C.M. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein- .2. Eur Spine J 16, 1257, 2007.
8. Bagaria, A., and Prasada, V. Bone morphogenetic protein: current state of filed and the road ahead. J Orthop 2, e3, 2005.
9. Boden, S.D., Kang, J., Sandhu, H., and Heller, J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 27, 2662, 2002.
10. McKay, W. Science-based assessment: accelerating product development of combination medical devices. Presented at the NMAB Roundtable on Biomedical Engineering Materials and Applications, Washington, DC, 2004.
11. FDA. InFUSE Bone Graft/LT-CAGE Lumbar Tapered Fusion Device. Summary of Safety and Effective Data Premarket Approval Application P000058, Rockville, MD, 2002.
12. Einhorn, T.A., Lane, J.M., Burstein, A.H., Kopman, C.R., and Vigorita, V.J. The healing of segmental bone defects induced by demineralized bone matrix. A radiographic and biomechanical study. J Bone Joint Surg Am 66, 274, 1984.
13. Alberius, P., and Gordh, M. Failure of onlay bone grafts to integrate over the calvarial suture: observations in adult isogeneic rats. J Craniomaxillofac Surg 24, 251, 1996.
14. Chou, Y.F., Dunn, J.C., and Wu, B.M. In vitro response of MC3T3-E1 pre-osteoblasts within three-dimensional apatitecoated PLGA scaffolds. J Biomed Mater Res B Appl Biomater 75, 81, 2005.
15. Lee, M., Li, W., Siu, R.K., Whang, J., Zhang, X., Soo, C., et al. Biomimetic apatite-coated alginate/chitosan microparticles as osteogenic protein carriers. Biomaterials 30, 6094, 2009.
16. Isobe, M., Yamazaki, Y., Mori, M., and Amagasa, T. Bone regeneration produced in rat femur defects by polymer capsules containing recombinant human bone morphogenetic protein-2. J Oral Maxillofac Surg 57, 695, 1999; discussion 9.
17. Lee, S.C., Shea, M., Battle, M.A., Kozitza, K., Ron, E., Turek, T., et al. Healing of large segmental defects in rat femurs is aided by RhBMP-2 in PLGA matrix. J Biomed Mater Res 28, 1149, 1994.
18. Zheng, Z., Yin, W., Zara, J.N., Li, W., Kwak, J., Mamidi, R., et al. The use of BMP-2 coupled-nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects. Biomaterials 31, 9293, 2010.
19. Yasko, A.W., Lane, J.M., Fellinger, E.J., Rosen, V., Wozney, J.M., and Wang, E.A. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats. J Bone Joint Surg 74, 659, 1992.
20. Lieberman, J.R., Daluiski, A., Stevenson, S., Wu, L., McAllister, P., Lee, Y.P., et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 81, 905, 1999.
21. Wu, G., Liu, Y., Iizuka, T., and Hunziker, E.B. Biomimetic coating of organic polymers with a protein-functionalized layer of calcium phosphate: the surface properties of the carrier influence neither the coating characteristics nor the incorporation mechanism or release kinetics of the protein. Tissue Eng Part C Methods 16, 1255, 2010.
22. Immunologic response to collagen-impregnated vascular grafts: a randomized prospective study. The Canadian Multicenter Hemashield Study Group. J Vasc Surg 12, 741, 1990.
23. Kirker-Head, C., Karageorgiou, V., Hofmann, S., Fajardo, R., Betz, O., Merkle, H.P., et al. BMP-silk composite matrices heal critically sized femoral defects. Bone 41, 247, 2007.
24. Quinn, J.M., Morfis, M., Lam, M.H., Elliott, J., Kartsogiannis, V., Williams, E.D., et al. Calcitonin receptor antibodies in the identification of osteoclasts. Bone 25, 1, 1999.
25. Takahashi, S., Goldring, S., Katz, M., Hilsenbeck, S., Williams, R., and Roodman, G.D. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast- like cell differentiation. J Clin Invest 95, 167, 1995.
26. Smucker, J.D., Rhee, J.M., Singh, K., Yoon, S.T., and Heller, J.G. Increased swelling complications associated with offlabel usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) 31, 2813, 2006.
27. Dmitriev, A.E., Farhang, S., Lehman, R.A., Jr., Ling, G.S., and Symes, A.J. Bone morphogenetic protein-2 used in spinal fusion with spinal cord injury penetrates intrathecally and elicits a functional signaling cascade. Spine J 10, 16, 2010.
28. Sciadini, M.F., and Johnson, K.D. Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res 18, 289, 2000.
29. Jin, W., Takagi, T., Kanesashi, S.N., Kurahashi, T., Nomura, T., Harada, J., et al. Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad proteins. Dev Cell 10, 461, 2006.
30. Aghaloo, T., Jiang, X., Soo, C., Zhang, Z., Zhang, X., Hu, J., et al. A study of the role of Nell-1 gene modified goat bone marrow stromal cells in promoting new bone formation. Mol Ther 15, 1872, 2007.
31. Rosen, E.D., and Spiegelman, B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276, 37731, 2001.
32. Takada, I., Kouzmenko, A.P., and Kato, S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 5, 442, 2009.
33. Takada, I., and Kato, S. Molecular mechanism of switching adipocyte/osteoblast differentiation through regulation of PPAR-gamma function. Clin Calcium 18, 656, 2008.
34. Justesen, J., Stenderup, K., Eriksen, E.F., and Kassem, M. Maintenance of osteoblastic and adipocytic differentiation potential with age and osteoporosis in human marrow stromal cell cultures. Calcif Tissue Int 71, 36, 2002.
35. Moerman, E.J., Teng, K., Lipschitz, D.A., and Lecka-Czernik, B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/ BMP signaling pathways. Aging Cell 3, 379, 2004.
36. Krause, U., Harris, S., Green, A., Ylostalo, J., Zeitouni, S., Lee, N., et al. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci USA 107, 4147, 2010.
37. Mroz, T.E., Wang, J.C., Hashimoto, R., and Norvell, D.C. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 35, S86, 2010.
38. Mindea, S.A., Shih, P., and Song, J.K. Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. Spine (Phila Pa 1976) 34, 1480, 2009; discussion 5.
39. MacDonald, K.M., Swanstrom, M.M., McCarthy, J.J., Nemeth, B.A., Guliani, T.A., and Noonan, K.J. Exaggerated inflammatory response after use of recombinant bone morphogenetic protein in recurrent unicameral bone cysts. J Pediatr Orthop 30, 199, 2010.
40. Mroz, T.E., Wang, J.C., Hashimoto, R., and Norvell, D.C. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 35, S86, 2010.
41. Kanayama, M., Hashimoto, T., Shigenobu, K., Yamane, S., Bauer, T.W., and Togawa, D. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein- 1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine (Phila Pa 1976) 31, 1067, 2006.
42. Shenker, N., Haigh, R., Roberts, E., Mapp, P., Harris, N., and Blake, D. A review of contralateral responses to a unilateral inflammatory lesion. Rheumatology (Oxford) 42, 1279, 2003.
43. Perri, B., Cooper, M., Lauryssen, C., and Anand, N. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study. Spine J 7, 235, 2007.
44. Buttermann, G.R. Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion. Spine J 8, 426, 2008.
45. Cunningham, N.S., Paralkar, V., and Reddi, A.H. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc Natl Acad Sci USA 89, 11740, 1992.
46. Chan, B.Y., Gartland, A., Wilson, P.J., Buckley, K.A., Dillon, J.P., Fraser, W.D., et al. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 40, 149, 2007.
47. Irie, K., Alpaslan, C., Takahashi, K., Kondo, Y., Izumi, N., Sakakura, Y., et al. Osteoclast differentiation in ectopic bone formation induced by recombinant human bone morphogenetic protein 2 (rhBMP-2). J Bone Miner Metab 21, 363, 2003.
48. Itoh, K., Udagawa, N., Katagiri, T., Iemura, S., Ueno, N., Yasuda, H., et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology 142, 3656, 2001.
49. Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Luthy, R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309, 1997.
50. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95, 3597, 1998.
51. Glass, D.A., 2nd, Bialek, P., Ahn, J.D., Starbuck, M., Patel, M.S., Clevers, H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8, 751, 2005.
52. Wan, Y., Chong, L.W., and Evans, R.M. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 13, 1496, 2007.
53. Mannion, R.J., Nowitzke, A.M., and Wood, M.J. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2-but what is the cost? Spine J 2010. doi:10.1016/j.spinee.2010.07.005.
54. Vaidya, R., Weir, R., Sethi, A., Meisterling, S., Hakeos, W., and Wybo, C.D. Interbody fusion with allograft and rhBMP- 2 leads to consistent fusion but early subsidence. J Bone Joint Surg Br 89, 342, 2007.